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This study aimed to determine the prevalence of normal and abnormal cervical cytology in women 
who attended the cervical cancer screening clinic of the Department of Medical Research in Lower 
Myanmar,  and to determine the proportion of high-risk (HR) human papillomavirus (HPV) infection 
and HPV genotypes in women with normal and abnormal cervical cytology.  A total of 1,771 women 
were screened from 2010 to 2011.  Among them,  762 women (43.0ｵ) had a normal smear,  and 866 
(48.9ｵ) and 87 (4.9ｵ) were diagnosed with inﬂammatory smears and atypical squamous cells of unde-
termined signiﬁcance (ASCUS),  respectively.  Diagnoses of low-grade squamous intraepithelial lesion 
(LSIL) and high-grade squamous intraepithelial lesion (HSIL) numbered 42 (2.3ｵ) and 11 (0.6ｵ) respec-
tively.  Three cases of squamous cell carcinoma (SCC) (0.2ｵ) were detected.  Cervical swabs were col-
lected from 96 women with abnormal cervical cytology and 20 with normal cytology.  HR-HPV DNA 
testing was performed by polymerase chain reaction (PCR) with pU1M/pU2R primers.  HR-HPV were 
identiﬁed in 35.5ｵ (22/62) of inﬂammatory smears,  60ｵ (6/10) of ASCUS,  86.7ｵ (13/15) of LSIL,  50ｵ 
(3/6) of HSIL,  100ｵ (3/3) of SCC and 5ｵ (1/20) of normal cytology.  In PCR-positive cases,  HPV 
genotyping was analyzed by the cleaved ampliﬁcation polymorphism method.  The most prevalent HPV 
genotypes were HPV-16 (60.4ｵ) followed by HPV-31 (14.6ｵ),  HPV-18 (12.5ｵ) and HPV-58 (12.5ｵ).  
Women with abnormal cervical cytology were 10 times more likely to be HR-HPV positive than those 
with normal cytology (p＝0.0001).  This study suggests that the implementation of a cervical cytology 
screening program and routine vaccination against HPV in preadolescent and adolescent groups are 
needed to reduce the burden of HPV-associated cervical cancer.
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orldwide,  cervical cancer is the third-most-
common cancer in women and the seventh overall 
with an estimated 530,000 new cases in 2008.  More 
than 85ｵ of the global burden occurs in developing 
countries,  where it accounts for 13ｵ of all female 
cancers.  Cervical cancer remains the most common 
cancer in women in Eastern Africa,  South-Central 
Asia and Melanesia.  Overall,  the mortality-to-incidence 
ratio is 52ｵ,  and cervical cancer was responsible for 
275,000 deaths in 2008,  about 88ｵ of which occurred 
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in developing countries.  According to the WHO 
South-East Asia region (SEARO) report,  there was 
an estimated 188,000 new cervical cancer cases and 
102,000 deaths in 2008 [1].  This is due to the fact 
that the majority of women in the world do not have 
access to cervical screening,  which can prevent up to 
75ｵ of cervical cancers [2].
　 In Myanmar,  over the past 30 years (1976-2006) 
cervical cancer has comprised 13,181 (23.5ｵ) of the 
total 56,097 known female cancer cases,  and cervical 
cancer and breast cancer traded places as the most 
common and second most common female cancers in 
those years [3].
　 Worldwide,  human papillomavirus (HPV) -16 and 
-18,  the 2 vaccine-preventable types,  contribute to 
over 70ｵ of all cervical cancer cases,  between 41ｵ 
and 67ｵ of high-grade cervical lesions and 16-32ｵ 
of low-grade cervical lesions.  In South-Eastern Asia,  
the prevalence of HPV-16 and HPV-18 by cytology is 
72.6ｵ in cervical cancer,  33.3ｵ in high-grade squamous 
intraepithelial lesions (HSIL),  14.2ｵ in low-grade 
squamous intraepithelial lesions (LSIL) and 3.2ｵ in 
normal cytology [4].  HPV can be identiﬁed in virtu-
ally all 99.7ｵ of cervical cancer cases and has been 
established as an etiological agent of invasive cervical 
cancer [5],  and it is the most common sexually trans-
mitted viral infection worldwide.  Persistent infection 
with oncogenic or high-risk HPV (HR-HPV) is neces-
sary for the development of premalignant lesions and/
or progression of the disease [6].
　 The HPV prevalence and genotype distribution are 
important for estimating the impact of HPV-based 
cervical cancer screening and HPV vaccination on the 
incidence of diseases etiologically linked to HPV.  The 
distribution of HPV genotypes varies across diﬀerent 
populations and geographical regions [7].  Only lim-
ited data have been available from Myanmar on the 
distribution of HPV genotypes in the general popula-
tion and in low-grade and high-grade lesions of the 
cervix and of cervical cancer.
　 Yet,  with the advent of preventive HPV vaccines 
that target HPV-16 and -18,  which are responsible 
for causing about 70ｵ of invasive cervical cancer in 
the world,  such information is crucial to predicting 
how vaccination and HPV-based screening would aﬀect 
the prevalence of cervical cancer.  This study aimed to 
determine the prevalence of normal and abnormal 
cervical cytology in women who attended the cervical 
cancer screening clinic of the Department of Medical 
Research in Lower Myanmar,  and to determine the 
proportion of HR-HPV in women with normal and 
abnormal cervical cytologies.
Materials and Methods
　 A total of 1,771 women attending the cervical 
cancer screening clinic at the Department of Medical 
Research in Lower Myanmar (DMR-LM) were screened 
during 2010 to 2011.  Among them,  762 had normal 
cytology and 1,009 had abnormal cytology.  Because of 
limited resources for further study,  we randomly 
selected 96 women with abnormal cervical cytology 
and 20 with normal cytology for HPV-DNA testing 
and genotyping.  Cervical swabs were taken after 
informed consent was obtained,  and those cervical 
cells were collected in phosphate buﬀer saline and 
stored at －20℃.
　 DNA extraction. For DNA extraction,  the 
samples were suspended in 300µL of proteinase K and 
incubated at 50℃ for 2h,  then treated with 100µL of 
5-M NaCl.  After centrifugation,  the supernatant was 
treated with 900µL of ethanol.  DNA precipitates were 
collected by centrifugation at 12,000rpm for 10min 
and washed with 400µL of 70ｵ ethanol.  DNA was 
dissolved in 100µL of TE.
　 High-risk human papillomavirus testing.
In this study,  HR-HPVDNA testing was performed in 
96 women with abnormal cervical cytology and 20 with 
normal cytology; and their ages ranged from 18 to 69 
years.  HPV-DNA testing was performed using the 
polymerase chain reaction (PCR) method.  Consensus 
sequence primer pairs within the E6 and E7 open 
reading frames,  i.e.,  forward primer (pU-1M): 5ʼ-TG 
TCAAAAACCGTTGTGTCC-3ʼ and reverse primer 
(pU-2R): 5ʼ-GAGCTGT CGCTTAATTGCTC-3ʼ) 
(oligo@sigma genosys-PCR,  Japan),  were used to 
amplify HR-HPV (HPV-16,  -18,  -31,  -33,  -35,  -52b,  
and -58) [8].  The reaction mixture included 0.15µL 
of taq polymerase (Applied Biosystems,  Roche,  CA,  
USA),  2µL 10X buﬀer,  3.2µL dNTPs,  0.4µL of 
forward and reverse primers,  12.85µL distilled water 
and 1µL DNA.  They were subjected to 35 cycles of 
ampliﬁcation using ASTEC thermal cycler.  Each cycle 
included a denaturation,  annealing and extension step.  
PCR using β-globin primers,  i.e.,  forward primer:  
5ʼ-GACACCATGGT GCACCTGAC-3ʼ and reverse 
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primer: 5ʼ-CCAATAGGCAGAGAGAGTCA-3ʼ―
was also performed for the detection of human DNA 
integrity.  Detection of the PCR products was per-
formed by electrophoresis on 6ｵ polyacrylamide gel 
(PAGE),  200V,  30 minutes and silver staining.
　 HPV genotyping. In PCR-positive cases,  HPV 
genotyping was analyzed by the cleaved ampliﬁed 
polymorphic 6-sequence (CAPS) method.  HR-HPV 
genotypes were detected by polyacrylamide gel elec-
trophoresis and silver staining of the digestion of PCR 
product with restriction enzyme(s),  Ava II (HPV-16,  
HPV-18 and HPV-33),  Rsa I (HPV-31),  Bgl II 
(HPV-52b),  Acc I (HPV-58) and Ava I (HPV-35) 
(Wako,  Japan).  The enzymatic digestion was per-
formed under the conditions recommended by the 
manufacturer [8].
　 Statistical Analysis. Data analysis was done 
using Microsoft Oﬃce Excel 2007 and the Statistical 
Package for Social Sciences (SPSS-15) i.e.,  SPSS 
full-version with free download (＜http://en. softonic.
com/s/spss-15-full-version-free-download/＞,  accessed 
October 2012).
Results
　 A total of 1,771 women were screened for the 
cervical cancer  from 2010 to 2011.  Among them,  762 
women (43.0ｵ) had normal smears,  and 866 (48.9ｵ) 
and 87 (4.9ｵ) were diagnosed as inﬂammatory smears 
and atypical squamous cells of undetermined signiﬁ-
cance (ASCUS) respectively.  In addition,  LSIL and 
HSIL numbered 42 (2.3ｵ) and 11 (0.6ｵ) respec-
tively.  Three cases of cervical cancer (0.2ｵ) were 
detected (Table 1).
　 High-risk human papillomavirus testing.
HR-HPV DNA testing was performed in 116 women:  
96 with abnormal cervical cytology and 20 with nor-
mal cytology,  whose ages ranged from 18 to 69 years.  
All samples (100ｵ) were ampliﬁed with β-globin 
primers which were used to ensure human DNA integ-
rity (Fig.  1).  Among them,  48 (41.4ｵ) women were 
positive for HR-HPV PCR revealing a band around 
240-260bp (Figs.  2A,  B).  HR-HPV was identiﬁed in 
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Fig. 1　 Ampliﬁcation of sample DNA using β globin primers M: molecular marker ФX174/HaeIII digest; lane 1 to 11 HPV-positive 
human DNA.
Table 1　 Cytology screening of women attending cervical cancer 
screening clinic,  Department of Medical Research-Lower Myanmar 
in 2010-2011
Cytology report No of cases Percentage (%)
Normal Smear 762 43.0
Inﬂammatory Smear 866 48.7
ASCUS＊ 87 4.9
LSIL＊＊ 42 2.3
HSIL＊＊＊ 11 0.6
SCC＊＊＊＊ 3 0.2
Total 1,771 100
＊Atypical squamous cells of undetermined signiﬁcance; ＊＊Low 
grade squamous intraepithelial lesion; ＊＊＊High grade squamous 
intraepithelial lesion; ＊＊＊＊Squamous cell carcinoma.
48.9ｵ (47/96) of subjects with abnormal cervical 
cytology and 5ｵ (1/20) of those with normal cytology.  
Among women with abnormal cervical cytology,  
HR-HPV was determined in 35.5ｵ (22/62) cases of 
inﬂammatory smear,  60ｵ (6/10) cases of ASCUS,  
86.7ｵ (13/15) of LSIL,  50ｵ (3/6) of HSIL,  and 
100ｵ (3/3) of squamous cell carcinoma (SCC) 
(Table 2).  The women with abnormal cervical cytology 
were 10 times more likely to be HR-HPV-positive 
than those with normal cytology (P＝0.0001).
　 HPV genotyping. Among 48 HPV-PCR-positive 
cases using Ava II digestion,  29 samples showed 2 
fragments,  about 155-bp and 80-bp bands,  indicating 
the HPV 16 genotype,  and 6 appeared in 170-bp and 
90-bp bands,  indicating the HPV 18 genotype (Fig.  
3A),  but 13 samples were undigested with Ava II,  Ava I 
and Bgl II.  These were further digested with Rsa I and 
Acc I.  Seven samples digested using Rsa I showed a 
broad band with 2 overlapping fragments of ～119-bp 
and 114-bp regions,  indicating the HPV-31 genotype 
(Fig 3B).  Six samples using Acc I showed a broad band 
of overlapping ～126-bp and 118-bp regions,  indicat-
ing the HPV-58 genotype (Fig.  3C).
　 The most prevalent HPV genotypes were HPV-16 
(60.4ｵ) followed by HPV-31 (14.6ｵ),  HPV-18 
(12.5ｵ) and HPV-58 (12.5ｵ).  HPV genotypes 16,  
18,  31 and 58 constituted 11 (50ｵ),  2 (9.1ｵ),  5 
(22.7ｵ),  and 4 (18.2ｵ) of the 22 cases of inﬂamma-
tory smear,  and 9 (69.2ｵ),  3 (23.1ｵ),  1 (7.7ｵ) and 
0ｵ of the 13 LSIL cases,  respectively.  HPV-16 
and -58 were present in 4 (66.7ｵ) and 2 (33.3ｵ) 
cases of the 6 women with ASCUS.  All cases of HSIL 
were HPV 16.  Among women with cervical cancer,  
66.7ｵ were genotyped as HPV 16 and 33.3ｵ as 
HPV 18 (Table 3).
　 Most patients infected with HR-HPV were aged 
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Fig. 2　 Ampliﬁcation of HPV using pU1M/pU2R primers showing lane M,  molecular marker: ФX174/HaeIII digest; (A) lane 1-negative 
control,  lane 2-positive control,  lanes 3 to 10-positive HPV DNA,  lane 11-negative HPV DNA (B) lane 10-negative control,  lane 11-posi-
tive control,  lanes-1,  3,  4,  5,  6,  7,  9-positive HPV DNA; lane 2,  8-negative HPV-DNA.
Table 2　 Proportion of high-risk human papillomavirus (HPV) 
genotypes in women with cervical cytological abnormalities
Cytology
HPV-PCR
Total
Positive Negative
Normal  1
(5.0%)
19
(95.0%)
20
Inﬂammatory Smear 22
(35.5%)
40
(64.5%)
62
ASCUS  6
(60.0%)
 4
(40.0%)
10
LSIL 13
(86.7%)
 2
(13.3%)
15
HSIL  3
(50%)
 3
(50%)
6
SCC  3
(100%)
 0
(0%)
3
Total Count
(% within cytology)
48
(41.4%)
68
(58.6%) 116
for abbreviation,  see Table 1
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Fig. 3　 HPV PCR products digested with restriction enzymes (A) Ava II showing lane 1-positive control of HPV 16,  lane 2,  3,  6,  8,  
9-HPV 16,  lane 4,  5-HPV 18,  lane 7-not completely digested; (B) Rsa I showing lane 1-positive control of HPV 31,  Lanes 2 to 8-HPV 
31; (C) Acc I showing lane 4-positive control of HPV 58,  lanes 1,  2,  3-HPV 58; lanes M in all ﬁgures-molecular marker: ФX174/HaeIII 
digest.
Table 3　 Proportion of high-risk human papillomavirus (HPV) genotypes in women with cervical cytological abnormalities
HPV genotypes
Age range (Years)
Total
20-29 30-39 40-49 50-59 60-69
HPV 16 1
(3.4%)
10
(34.5%)
13
(44.8%)
3
(10.3%)
2
(6.9%)
29
HPV 18 0
(0%)
0
(0%)
3
(50.0%)
3
(50.0%)
0
(0%)
6
HPV 31 1
(14.3%)
2
(28.6%)
2
(28.6%)
1
(14.3%)
1
(14.3%)
7
HPV 58 1
(16.7%)
2
(33.3%)
1
(16.7%)
1
(16.7%)
1
(16.7%)
6
Total (Count)
(% within genotype)
3
(6.3%)
14
(29.2%)
19
(39.6%)
8
(16.7%)
4
(8.3%) 48
40-49 years (39.6ｵ),  followed by 30-39 years (29.2ｵ),  
50-59 years (16.7ｵ),  60-69 years (8.3ｵ) and 20-29 
years (6.3ｵ) (Fig.  4A).  HPV-16 was highest among 
women 40-49 years (44.8ｵ),  followed by 30-39 
years (34.5ｵ) (Fig.  4B).  As for HPV-18,  the detec-
tion rate was the same for women 40-49 years and 
50-59 years (Fig.  3B).  HPV-31 was high in the age 
ranges of 30-39 years and 49-49 years (Fig.  3C).  
HPV-58 was high in the age range of 30-39 years old 
(33.3ｵ) and was essentially the same in all other age 
groups (Fig.  3D).
Discussion
　 The incidence of cervical cancer varies dramati-
cally across the world,  largely depending on the avail-
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(B) HPV 16
(A) HPV infection
(C) HPV 18
(D) HPV 31 (E) HPV 58
Fig. 4　 Proportion of (A) HPV infection,  (B) HPV 16,  (C) HPV 18,  (D) HPV 31,  (E) HPV 58 in women with cervical cytological 
abonormalities by age group.
ability and accessibility of cervical screening pro-
grams.  Most places in South America and South and 
West Africa have an age-standardized incidence above 
20 per 100,000 women per year; some places in these 
regions have reached 40 per 100,000 women per year.  
In contrast,  the age-standardized incidence rates are 
below 10 per 100,000 women per year in North America,  
Western Europe,  Australia and New Zealand.  Even 
within Asia,  the age-standardized incidence varies 
substantially,  with 9.6 per 100,000 women per year in 
East Asia,  15.8 per 100,000 women per year in 
South-Eastern Asia,  24.6 per 100,000 women per year 
in South-Central Asia and 4.5 per 100,000 women per 
year in Western Asia [9].
　 Human papillomaviruses have a small double-
stranded DNA genome about 8kb in length.  To date,  
more than 120 types of HPV have been well charac-
terized,  of which about 40 types can infect the genital 
tract [3].  About 15 types of these genital (mucosal) 
HPVs are classiﬁed as “high-risk” because of their 
oncogenic or possible oncogenic properties,  either 
demonstrated by in vitro biochemical studies or inferred 
from epidemiological observations [10,  11].
　 HPV epidemiology can be undertaken in terms of 
type distribution of cervical HPV infection in women 
with normal cytology or in those with abnormal cytol-
ogy.  A meta-analysis of relevant studies about the 
worldwide prevalence and type distribution of cervical 
HPV DNA in women with normal cytology was recently 
published.  In this manuscript,  the overall HPV 
prevalence was estimated to be 10.4ｵ.  However,  
there were some diﬀerences depending on the region 
of origin.  HPV-16 is the most common HPV type,  
and the5 most common HPV types in women world-
wide were HPV-16,  -18,  -31,  -58 and -52,  
together comprising 50ｵ of all HPV infections [7].
　 Zuna RE et al. [12] focused on the distribution of 
HPV genotypes in women with cervical lesions,  and 
found that HPV-16 and -18 were the most frequent 
HPV types identiﬁed in invasive cancers (80ｵ) but 
that the distribution patterns of HPV types in intra-
epithelial lesions were highly varied.  Cobo F et al. 
[13] published HPV type distributions in females with 
abnormal cervical cytology,  and showed that 75ｵ 
were positive for HPV DNA and 23.7ｵ were nega-
tive.  HPV-16 was the most common type followed by 
HPV-58,  -51,  -33,  -31 and -18.
　 Recently,  Tachezy R et al. [14] reported that 
HPV-16 was the most prevalent type both in precan-
cerous lesions (45ｵ) and squamous cell carcinomas 
(59ｵ).  HPV-16 and/or -18 was present in 76ｵ of 
cervical cancer samples,  33ｵ of CIN1,  43ｵ CIN2 
and 71ｵ of CIN3.  Takehara K et al. [16] showed 
that HPV genotypes were detected in 9.5ｵ of women 
testing negative for intraepithelial lesion or malig-
nancy (NILM),  and 72.2ｵ of ASCUS or other cervi-
cal lesions.  In this study,  HPV genotypes were as 
follows: HPV-52 at 26.6ｵ,  HPV-16 at 25.2ｵ,  
HPV-58 at 21.8ｵ,  and HPV-18 at 7.1ｵ.
　 As for Myanmar,  Mu-Mu-Shwe et al. (2009,  
Myanmar Health Research Congress) reported that the 
prevalence of HPV in women with premalignant and 
malignant lesions of the cervix was 77 in 145 (53.1ｵ).  
HPV was identiﬁed in 33.3ｵ of LSIL,  60ｵ of HSIL,  
58.7ｵ of SCC and 50ｵ of adenocarcinoma of the 
cervix.  HPV-16 was the predominant genotype,  fol-
lowed by HPV-31 and HPV-18.  Thein Myint Thu et 
al. (2009,  Myanmar Health Research Congress) 
reported that HPV DNA was detected in 27 of 131 
(20.6ｵ) women tested,  including 17.6ｵ of those with 
a normal smear,  77.1ｵ with an inﬂammatory smear,  
0.8ｵ of LSIL and 4.6ｵ with an unsatisfactory smear.
　 In the present study,  47 of 96 (49ｵ) women with 
abnormal cervical cytology and 1 of 20 (5ｵ) with 
normal cytology were positive for high-risk human 
papillomavirus (HR-HPV).  HPV was identiﬁed in 
35.5ｵ of those with an inﬂammatory smear,  60ｵ of 
ASCUS,  86.7ｵ of LSIL,  50ｵ of HSIL and 100ｵ 
of SCC.  The prevalence of HPV in the present study 
was much higher than that in the previous one (86.7ｵ 
vs. 33.3ｵ in LSIL,  100ｵ vs. 58.7ｵ in SCC sam-
ples.  The highest percentage of women with positive 
results for HR-HPV was found in patients with LSIL 
and cervical cancer.  Therefore,  HPV DNA testing 
could be especially useful for triage of low-grade 
smears to improve the sensitivity of cytology alone and 
select women at greater risk who require colposcopy.
　 The most prevalent HPV genotype in this study was 
HPV-16,  one of the vaccine-preventable HPV geno-
types (60.4ｵ),  which was consistent with other stud-
ies mentioned above,  followed by HPV-31 (14.6ｵ),  
HPV-18 (12.5ｵ) and HPV-58 (12.5ｵ).  Among cer-
vical cancer cases,  66.7ｵ were genotyped as HPV-
16 and 33.3ｵ as HPV-18.  Clinical studies of HPV 
vaccines have demonstrated close to 100ｵ protection 
against HPV-16 and HPV-18 related infections and 
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diseases,  implying potential cross-protection against 
HPV-31,  -33,  -45,  -52,  and -58 [16,  17].
　 In this study,  most patients infected with HR-HPVs 
and the HPV-16 genotype were ages 40-49 years,  
followed by those in the 30-39 age range.  As for 
HPV-18,  the detection rate was the same in the 40-49 
and 50-59 age ranges.  HPV-31 was highest for ages 
30-39 and 49-49.  HPV-58 was highest in ages 30-39 
years.  A study by Takehara K et al. [15] reported 
that most patients infected with HPV-16 were 20-29 
years,  decreasing with age thereafter.  HPV preva-
lence by age revealed higher infection rates in young 
women aged 15-25 years with a second peak in women 
55 years or older.
　 The analysis described here does not need isotopes 
and is therefore convenient,  especially where facilities 
to handle radioactive substances are not available.  
The procedure is simpler than dot blot hybridization 
and can be performed within a day,  although this 
system is less sensitive than dot blot hybridization 
using isotopes.  Digestion of PCR products with 
restriction enzymes could identify HPV-speciﬁc geno-
types eﬃciently in clinical samples.  In the same way,  
any combination of mixed infection could be identiﬁed 
because restriction fragments from each HPV type are 
of diﬀerent sizes.  But the decision of HPV genotypes 
by the PCR-RFLP method alone is sometimes diﬃcult 
since various nucleotide replacements frequently occur 
in the sequence of HPV DNA.  It is considered that 
the sequencing method might be a better way to geno-
type HPV.  This restriction enzyme analysis method 
followed by sequence analysis is particularly useful for 
identifying potentially new HPV types.
　 HPV infections occur with a high attack rate soon 
after sexual initiation.  Follow-up studies in several 
countries of virgins after their sexual debut have 
shown up to 70ｵ of women becoming HPV DNA 
positive at least once within 48 months.  The cumula-
tive lifetime exposure to HPV has been estimated to 
be close to 80ｵ; for HPV-16 or -18 it is 20ｵ.  
Thus,  primary prevention with HPV vaccines should 
focus on the years before sexual initiation,  in adoles-
cent and pre-adolescent age groups [18].
　 In the future,  HPV DNA testing in conjunction 
with cervical cytology testing could be used for cervi-
cal cancer screening or in a follow-up program after 
conservative treatment of cervical lesions since 35.5ｵ 
of inﬂammatory smears,  60ｵ of ASCUS and 86.7ｵ 
of LSIL were HR-HPV positive.  If no intervention is 
implemented in the near future,  a dramatic increase in 
the numbers of cervical cancer cases is predicted.  
HPV vaccines oﬀer an eﬃcient way to prevent HPV-
related cervical cancers.  Results of this study 
together with those of several other studies help us to 
estimate the potential beneﬁt that could be achieved by 
the implementation of routine vaccination for the pre-
vention of HPV-associated cervical cancer in Myanmar.
　 In conclusion,  the most prevalent HPV genotypes 
in this study were HPV-16,  followed by HPV-31,  
HPV-18 and HPV-58.  Among cervical cancer cases,  
the vaccine-preventable HPV genotypes,  i.e.  HPV-16 
and HPV-18,  comprised 66.7ｵ and 33.3ｵ,  respec-
tively.  Women with abnormal cervical cytology were 
10 times more likely to be HR-HPV positive than those 
with normal cytology.  This study suggests that the 
implementation of a routine vaccination program 
against HPV in preadolescent and adolescent age 
groups would greatly reduce the burden of HPV-
associated cervical cancer in Myanmar.
Acknowledgments. We are grateful to all the staﬀs of the Cervical 
Cancer Screening Clinic,  Department of Medical Research (Lower 
Myanmar).
References
 1. World Health Organization: GLOBOCAN 2008.  International Agency 
for Research on Cancer (IARC),  Section of Cancer Information 
(23/11/2011).
 2. Bosch FX,  de Sanjose S and Castellsague X: HPV and genital 
cancer: the essential epidemiology; in Vaccines for the prevention 
of cervical cancer,  Stern PL and Kitchener HC eds,  Oxford University 
Press,  Oxford (2008) 4: 36.
 3. Soe Aung: Epidemiological overview of cervical cancer.  Yangon 
Cancer Registry (1974-2006),  Yangon.
 4. WHO/ICO Information Centre on HPV and Cervical Cancer.  
Human Papillomavirus and Related Cancers in Laos.  Summary 
Report 2009.
 5. Walboomers JM,  Jacobs MV,  Manos MM,  Bosch FX,  Kummer 
JA,  Shah KV,  Snijders PJ,  Peto J,  Meijer CJ and Muñoz N:  
Human papillomavirus is a necessary cause of invasive cervical 
cancer worldwide.  J Pathol (1999) 189: 12-19.
 6. Ho GY,  Burk RD,  Klein S,  Kadish AS,  Chang CJ,  Palan P,  Basu 
J,  Tachezy R,  Lewis R and Romney S: Persistent genital human 
papillomavirus infection as a risk factor for persistent cervical dys-
plasia.  J Natʼl Cancer Inst (1995) 87: 1365-1371.
 7. de Sanjosé S,  Diaz M,  Castellsagué X,  Cliﬀord G,  Bruni L,  
Muñoz N and Bosch FX: Worldwide prevalence and genotype dis-
tribution of cervical human papillomavirus DNA in women with nor-
mal cytology: a meta-analysis.  Lancet Infect Dis (2007) 7: 453-
459.
 8. Fujinaga Y,  Shimada M,  Okazawa K,  Okazawa K,  Fukushima M,  
86 Acta Med.  Okayama　Vol.  68,  No.  2Mu-Mu-Shwe et al.
Kato I and Fujinaga K: Simultaneous detection and typing of geni-
tal human papillomavirus DNA using the polymerase chain reac-
tion.  J Gen Virol (1991) 72: 1039-1044.
 9. Ferlay J,  Shin HR,  Bray F,  Forman D,  Mathers C and Parkin DM:  
Estimate of worldwide burden of cancer in 2008,  GLOBOCAN 2008.  
Int J Cancer (2010) 127: 2893-2917.
10. Munoz N,  Bosch FX,  de Sanjose S,  Herrero R,  Castellsague X,  
Shah KV,  Snijders PJ and Meijer CJ: International Agency for 
Research on Cancer Multicenter Cervical Cancer Study Group.  
New Eng J Med (2002) 346: 1105-1112.
11. Schiﬀman M,  Herrero R,  Desalle R,  Hildesheim A Wacholder S,  
Rodoriguez AC,  Bratti MC,  Sherman ME,  Morales J,  Guillen D,  
Alfaro M,  Hutchinson M,  Wright TC,  Solomon D,  Chen Z,  
Schussler J,  Castle PE and Burk RD: The carcinogenicity of 
human papillomavirus types reﬂects viral evolution.  Virology (2005) 
337: 76-84.
12. Zuna RE,  Allen RA,  Moore WE,  Lu Y,  Mattu R and Dunn ST:  
Distribution of HPV genotypes in 282 women with cervical lesions:  
evidence for three categories of intraepithelial lesions based on 
morphology and HPV type.  Mod Pathol (2007) 20: 167-174.
13. Cobo F,  Concha A and Oritz M: Human Papillomavirus (HPV) 
Type Distribution in Females with Abnormal Cervical Cytology.  A 
Correlation with Histological Study.  Open Virol J (2009) 3: 60-66.
14. Tachezy R,  Smahelova J,  Salakova M,  Arbyn M,  Rob L,  Skapa P,  
Jirasek T and Hamsikova E: Human Papillomavirus Genotype 
Distribution in Czech Women and Men with Diseases Etiologically 
Linked to HPV.  PLoS ONE (2011) 6: e21913,  doi: 10. 1371.
15. Takehara K,  Toda T,  Nishimura T,  Sakane UJ,  Kawakami Y,  
Mizunoe T,  Nishiwaki M and Taniyama K: Human Papillomavirus 
Types 52 and 58 Are Prevalent in Uterine Cervical Squamous 
Lesions from Japanese Women.  Pathol Res Int (2011) 7: e246936.  
doi: 10. 4061.
16. Harper DM,  Franco EL,  Wheeler CM,  Moscicki AB,  Romanowski B,  
Roteli-Marins CM Jenkins D,  Schuind A,  Costa Clemens SA and 
Dubin G: Sustained eﬃcacy up to 4.5 years of a bivalent L1 virus-
like particle vaccine against human papillomavirus types 16 and 
18: follow-up from a randomized control trial.  Lancet (2006) 367:  
1247-1255.
17. Paavonen JD,  Jenkins DFX,  Bosch FX,  Naud P,  Salmeron J,  
Wheeler CM,  Chow SN,  Apter DL,  Kitchener HC,  Castellsague X,  
de Carvalho NS,  Skinner SR,  Harper DM Hedrick JA,  Jaisamrarn 
U,  Limson GA,  Dionne M,  Quint W,  Spiessens B,  Peeters P,  
Struyf F,  Wieting SL,  Lehtinen MO and Dubin G: Eﬃcacy of a 
prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against 
infection with human papillomavirus types 16 and 18 in young 
women: an interim analysis of a phase III double blind,  random-
ized controlled trial.  Lancet (2007) 369: 2161-2170.
18. Bosch FX,  de Sanjose S and Castellsague X: HPV and genital 
cancer: the essential epidemiology.  in Vaccines for the prevention 
of cervical cancer,  in Stern PL and Kitchener HC eds,  Oxford 
University Press,  Oxford (2008) 4: 45.
87Prevalence of High Risk HPV Infection in MyanmarApril 2014
